A review of relevant law reveals that the Trump administration is not nearly as hampered by antitrust law as the pharmaceutical benefits manager industry argues. Antitrust law does not prohibit manufacturers from offering discounts on drug prices, and antitrust law cannot justify the industry’s current aggressive use of rebates, according to a piece co-authored by Kevin Schulman.
https://www.healthaffairs.org/do/10.1377/hblog20190402.468158/full/